Nuwellis NUWE
Nuwellis FY 2023: revenue $8.9M, up 4%; diluted EPS −$21,111,893.03
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001140361-24-012644
- Document
- 10-K
- Exhibit 4.14
- Warrants or notes
Key figures from this report
These are the numbers Nuwellis reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$8.9M+4% from $8.5M in FY 202210-K income statement, on EDGAR
- Net income−$20.2MAgainst −$14.5M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$21,111,893.03Against −$153,116,203.38 in FY 2022. Split-adjusted, as the tables show it; the filing reported −$11.5210-K income statement, on EDGAR
- Cash and cash equivalents$3.8M−79% from $17.7M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$17.9MAgainst −$15.1M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Same SIC code (3845) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.
- ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
- Adm Tronics Unlimited ADMT public float $7M, Sep 30, 2025
- Escalon Medical ESMC public float $506K, Dec 31, 2025
- Yubo International Biotech YBGJ
- CapsoVision CV
